Equity Details
Price & Market Data
Price: $1.72
Daily Change: +$0.0747 / 4.33%
Daily Range: $1.63 - $1.75
Market Cap: $452,443,584
Daily Volume: 1,043,363
Performance Metrics
1 Week: 8.86%
1 Month: 12.42%
3 Months: 4.24%
6 Months: 39.84%
1 Year: 16.22%
YTD: -15.69%
About Autolus Therapeutics plc (AUTL)
Understand Autolus Therapeutics plc (AUTL)'s current market standing. Current price: 1.72, daily change: +$0.0747 / 4.33%. Market cap: 452,443,584. Detailed performance for all periods.
Company Details
Employees: 752
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United Kingdom
Details
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
